AZN241227C77000
- 0.00
- 0.000.00%
AstraZeneca Newsroom
ROSEN, LEADING INVESTOR COUNSEL Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
AstraZeneca (AZN) Faces Securities Class Action After Reports of PRC Probe Into Fraud and Corruption - Hagens Berman
AstraZeneca, Daiichi Sankyo Have Voluntarily Withdrawn a Dato-DXd MAA in EU
Quantum Computing Stocks Soar: How to Capture the Investment Opportunities?
AstraZeneca PLC ADR Underperforms Tuesday When Compared To Competitors
Achilles Therapeutics Transfers TRACERx Data and MAP Assets to AstraZeneca in $12M Agreement
Express News | Achilles Therapeutics Sells TRACERx And MAP Assets To AstraZeneca For $12M, Transferring Tumor Data And Samples; Concludes Strategic Review With Plans For Workforce And Board Reductions
Press Release: Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
London Shares Festive Ahead of Christmas Break; Vistry Slumps on Fresh Profit Warning
AstraZeneca Pulls EU Marketing Application for Lung Cancer Treatment Amid Regulatory Feedback
Astra, Daiichi Withdraw EU Application for Lung Cancer Drug
AstraZeneca Withdraws EU Application for Datopotamab Deruxtecan in Lung Cancer
Express News | US FDA: Revoked Emergency Use Authorization for AstraZeneca's Evusheld as of Dec 13 - Website
AstraZeneca PLC Stock Rises Monday, Underperforms Market
London Shares Rise; UK Economy Flatlines
Unusual Options Activity: COIN, AZN and Others Attract Market Bets, COIN V/OI Ratio Reaches 120.0
AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC
AstraZeneca's Blockbuster Drug Tagrisso Wins EU Nod for Non-small Cell Lung Cancer
AstraZeneca Obtains EU Approval for Tagrisso in Non-small Cell Lung Cancer Treatment
AstraZeneca's Tagrisso Gains EU Approval for Unresectable EGFR-Mutated Lung Cancer